

Because every care experience is personal.

13 August 2025

### Legal Disclaimer

This presentation contains general information about the activities of Oneview Healthcare PLC (ABRN 610 611 768) (Oneview or Company) which is current as at 13 August 2025. It is in summary form and does not purport to be complete. It presents financial information on a statutory basis, prepared in accordance with International Financial Reporting Standards (IFRS), as well as information provided on a non-IFRS basis. This presentation is not a recommendation or advice in relation to Oneview or any product or service offered by Oneview. It is not intended to be relied upon as advice to investors or potential investors and does not contain all information relevant or necessary for an investment decision. It should be read in conjunction with Oneview's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange and in particular the Half Year Results for the period ended to 30 June 2025. These are also available at www.oneviewhealthcare.com.

No representation or warranty, expressed or implied, is made as to the accuracy, adequacy or reliability of any statements, estimates or opinions or other information contained in this presentation. To the maximum extent permitted by law, Oneview, its subsidiaries and their respective directors, officers, employees and agents disclaim all liability and responsibility for any direct or indirect loss or damage which may be suffered by any recipient through use of or reliance on anything contained in or omitted from this presentation. No recommendation is made as to how investors should make an investment decision. Investors must rely on their own examination of Oneview, including the merits and risks involved. Investors should consult with their own professional advisors in connection with any acquisition of securities.

The information in this presentation is for general information only. To the extent that certain statements contained in this presentation may constitute "forward-looking statements" or statements about "future matters", the information reflects Oneview's intent, belief, or expectations at the date of this presentation. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Oneview disclaims any obligation or undertakings to disseminate any updates or revisions to this information over time. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Oneview's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any forward-looking statements, opinions and estimates in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. For example, the factors that are likely to affect the results of Oneview include, but are not limited to, general economic conditions in any of the territories in which Oneview operates, exchange rates, competition in the markets in which Oneview will operate and the inherent regulatory risks in the business of Oneview. Neither Oneview, nor any other person, gives any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this presentation will actually occur. In addition, please note that past performance is no guarantee or indication of future performance.

This presentation does not constitute an offer to issue or sell, or solicitation of an offer to buy, any securities or other financial products in any jurisdiction. The distribution of this presentation outside Australia may be restricted by law. Any recipient of this presentation outside Australia must seek advice on and observe any such restrictions. This presentation may not be reproduced or published, in whole or in part, for any purpose without the prior written permission of Oneview.

All amounts are in Euros unless otherwise specified. All references starting with FY refer to the year ended 31st December 2024. H1 refers to the period ended 30 June 2025 (H1 25).



Oneview Healthcare plc (ASX: ONE)

Healthcare technology company enabling the Connected Care Experience in hospitals and healthcare systems with a modular, scalable software platform that connects the patient room to the care team and the hospitals' technology systems, delivering efficiencies for the hospital and a better, more engaged care experience for patients

Founded in 2008 in Dublin, Ireland

ISO 27001, 27701 & 42001

#### **Our Mission**

To improve connected care experiences, every day

#### **Our Vision**

Redefining the digital environment of care to make it accessible, seamless and reliable for all

Our US footprint includes 3 hospitals that have been recognised in the top 20 nationwide \*





# **Speakers**



James Fitter
Chief Executive Officer



Darragh Lyons Chief Financial Officer

### Contents

1) H1 2025 in Review 2) H1 2025 Financial Results Overview

3) Reimagining the Patient Experience with AI

4) Commercial & Sales Updates

5) Deployment Updates

6) Outlook

7) Q&A





H1 2025 in Review

### H12025 Results

H12025

Revenue

€6.3m

(A\$10.9m)

Up 36%

**Recurring Revenue** 

€3.8m

(A\$6.5m)

 $\uparrow$ 

Up 7%

**Gross Margin** 

61%

(2024: 73%)

 $\downarrow$ 

Down 12%

Operating EBITDA

Loss

**€4.5m** (A\$7.7m)

 $\uparrow$ 

Up 21%

As at 30 June 2025

Cash

€8.2m



(31 December 2024:

(A\$14.7m)

€13.8)

2 new customer logos added



**Live Endpoints** 

13,526



Up (net) 1% in H1 25

Recurring Revenue per live endpoint per day

€1.54


Up 5% in H1 2025



First initiative from Oneview's AI Strategy was launched during H1 2025: Ovie, a Gen AI-powered Care Assistant



### 36% YoY Revenue Growth























A MEMBER OF THE MONTEFIORE HEALTH SYSTEM



### **ASX: ONE Investment Highlights**



- Progressing towards faster and more efficient deployments
- Embedding Al-powered solutions into every business function, yielding measurable performance improvements
- Restructured our Australian and other functional teams to align operations with current business opportunities and strategic priorities




- ) 2 new customer logos added during H1 2025
- Sales pipeline expanding and maturing with several late-stage pipeline opportunities
- Three-year contract extension secured with a key strategic customer, driving over 20% year-onyear growth in annual recurring revenue from this customer



- Developing a new User Experience which will be delivered during H2 2025
- Developing Al-powered patient engagement products having built a solid Al foundation
- Achieved ISO 42001 certification, becoming one of the first companies on the ASX and in the connected care sector to attain this certification for its AI Management System





### H12025 Financial Performance

36% growth in revenue

**7%** growth in recurring revenue

**H1 2025 Gross Margin** of **61%** (H1 2024: 73%) impacted by revenue mix (i.e. greater proportion of deployment revenue)

**Restructured** our global operations to better align Australian and functional operations with current strategic priorities

- ~10% reduction in global employee headcount
- continued focus on improving business efficiency

#### **Operating EBITDA¹ loss** of **€4.5 million** impacted by:

- Restructuring charges of €168k and;
- Previous investment in resources to support expected deployment activity from the Baxter and direct sales pipelines

	Period ended 30 June 2025	Period ended 30 June 2024	Variance
	€'m	€'m	%
Recurring revenue	3.8	3.6	7%
Non-recurring revenue	2.5	1.1	132%
Total Revenue	6.3	4.7	36%
Cost of sales	(2.5)	(1.3)	97%
<b>Gross Profit</b>	3.8	3.4	13%
Cash operating expenses	(8.3)	(7.1)	17%
Operating EBITDA loss	(4.5)	(3.7)	21%
Non-cash expenses:			
Share based payment expense	(1.6)	(1.7)	-3%
Depreciation & amortisation	(0.3)	(0.3)	3%
Net finance income / (costs)	(1.5)	0.1	-
Loss before tax	(7.9)	(5.5)	44%
Income tax expense	-	-	-
Loss after tax	(7.9)	(5.5)	44%

<sup>&</sup>lt;sup>1</sup> Operating EBITDA excludes deprecation, amortisation, finance & FX charges / gains and non-cash share based payment charges



### Financial Position as at 30 June 2025

Balance Sheet Position	As at 30 June 2025	As at 31 December 2024	Variance
	€'m	€'m	%
Cash and cash equivalents	8.2	13.8	-41%
Trade & other receivables	3.1	5.3	-42%
Inventory	2.6	3.1	-17%
Other assets	2.3	3.8	-39%
Total Assets	16.1	26.0	-38%
Trade and other payables	0.7	1.3	-46%
Deferred income	2.9	5.0	-42%
Accruals and other liabilities	5.1	6.4	-21%
Total Liabilities	8.6	12.7	-32%
Net Assets / Total Equity	7.5	13.3	-44%

Cash Flow Statement Summary	H1 2025	H1 2024	Variance
	€'m	€'m	%
Net cash used in operating activities	(4.8)	(5.2)	-8%
Net cash used in investing activities	-	(0.3)	-100%
Net cash generated by / (used in) financing activities	(0.2)	(0.1)	180%
Net decrease in cash held	(5.1)	(5.6)	-10%
Cash as at 1 January	13.8	11.5	20%
Foreign exchange impact on cash	(0.6)	0.1	n/a
Cash as at 30 June	8.2	6.0	37%

€8.2 million of Cash as at 30 June 2025

Lower cash burn in H1 2025 compared to H1 2024 driven by higher cash receipts, aligned with H1 2025 revenue

Restructuring executed in June 2025 reduced global headcount by ~10% and will deliver annual cost-savings of €1.1m

Strong inventory of our proprietary deployment hardware held in the US shields us from the current tariff and trading volatility

€1.5 million of debtors as at 30 June 2025 compared to €3.3 million at 31 December 2024





## Al-Driven Patient Engagement





### Faster speed to value and revenue



### What we build: Al-powered products

- Personalize engagement and experience to each patient's needs
- Monitors behavior and environment to surface realtime insights
- Anticipates needs and risks to guide timely staff action
- Orchestrates workflows to optimize efficiency



#### How we work: Al-powered delivery and operations

- Al Communities of Practice to share knowledge and skills across our teams
- Al-powered product research and prototyping
- Reimagined Software Development Lifecycle using Al Agents to accelerate software delivery



Our Al foundation: safe, responsible, capable

- Al Management System
  - Evaluation & Monitoring •
- Executive & Staff Upskilling
- Regulatory Compliance
- Only ASX listed company to date to be ISO 42001 certified




### Al Augmented Software Development Lifecycle

- Research & Ideation
- Product Context files
- Draft & review of PRDs (Product Requirements Documents)
- Draft Epic & Stories, descriptions, written as Al prompts

- Automated integration of design context (PRD, Epics, Stories) & instruction files to coding agents
- Code & test generation
- Automated code review
- Documentation generation

- Draft release documentation
- Draft customer comms

- Intelligent monitoring of production environments
- Incident triage & root cause analysis
- Automated feedback loop of issues to engineering teams



(accessible via MCP)



### Ovie ... Oneview's Al-Driven Ecosystem



#### Ovie, your virtual care team member

intelligence engine powering personalization, anticipation, orchestration, and context-awareness across the Oneview platform

#### **Patient Centric**



#### **Ovie Engage**

context-aware widget surfacing what's important for patients



#### **Ovie Voice**

enables natural, conversational interaction with Ovie



#### Care Team Centric

#### **Ovie Console**

real-time dashboard surfacing what's important for staff



#### **Ovie Rounds**


focused, context-aware rounding for staff and leaders





### Al-augmented hybrid care

Ensuring patients receive appropriate & timely care




### Innovation Update


#### **Patient Centric**

#### **Ovie Engage**






# Ovie Voice




### Care Team Centric















### Al-Powered Insights

#### **Identification of Patient Groups**


Behavioural clustering techniques uncover distinct groups of patients by analysing demographic characteristics, visit information and system utilization

#### **Personalised Interventions**

Insights from clustering enable the design of tailored optimizations to maximise system utilization and customer value

#### **Anticipating Issues**

Working with an innovation customer in the US to determine if Oneview behavioural data correlates to HCAHPS satisfaction data







### Our Global Footprint

Oneview customers in Australia, Thailand, Ireland and the US

Focused on US market to drive near-term significant growth aspirations, with opportunistic expansions in other regions


Proven ability to target other markets and opportunities in the future





### **US Customers**






## Commercial Strategy


- Adding new logos is obviously our key commercial focus
- Once new customers are "landed", we are able to demonstrate our products value and scalability in the customers production environment

Annual recurring revenue (software subs)





Very 'sticky' customers: low customer churn



#### Bilateral expansion:

- \* 92% product upsell
- \* enterprise-wide expansion




### New Customer Logos

Strong momentum in the sales pipeline positions us to land new customer logos in H2 2025

Several new logos in contract negotiations








### **Baxter Partnership**

Momentum is building as opportunities work their way through the funnel
















Baxter Partnership Potential





## The Connected Care Experience


We have evolved from a single platform solution to a suite of revenue-generating products and delivery channels

#### **Modular & Scalable:**


- √ 92% upsell opportunity with existing Care Experience customers
- Products can be sold as standalone

Management will track and report on endpoints (rather than beds) going forward


#### **MyStay Patient Devices**



#### **Digital Whiteboard**




#### **Digital Door Sign**





## Live Endpoints

Dec '25



> 20,000 Contracted Endpoints

#### Note:

894 endpoints decommissioned in June 2025 with Australian customer due to budgetary constraints offset by materially higher margin deployments in the U.S.



# Live Endpoints

Average recurring revenue per new endpoint installed was 96% higher than the endpoints decommissioned

This will represent an incremental ~€0.3 million in annual recurring revenue from H2 2025+

# Annualised recurring revenue per endpoint

(based on live endpoints at the end of the period):

2024

€1.47

H1 2025

€1.54



5% Growth (despite weakening USD in Q2)



### Our Path to More Efficient Deployments Continues

#### H1 & H2 2025

### Investing in configuration tooling

- to reduce project implementation times
- reduce on-going support overheads and costs
- enabling partners to install and operate the system

### Infrastructure automation with AI Agents

- optimisation of deployment pipelines
- optimisation of infrastructure-as-code
- continuation of migration to containers

# Exploration of Algenerated configuration

for complex feature configuration

#### H<sub>2</sub> 2025

#### Targeting 90-day deployments

- overhaul the deployment methodology
- get beds live faster
- accelerate commencement of recurring revenue
- reduce and remove inefficiencies
- standardise the configuration of the platform





### ONE H1 2025 Outlook



#### **Performance**

- 36% increase in Revenue during H1 2025 (compared to H1 2024)
- 7% increase in recurring revenue
- 5% increase in revenue per endpoint



#### **Pipeline**

- Record US sales
   opportunity pipeline
   comprised of potential
   direct sales and sales
   under the Baxter VAR
   partnership
- Several additional logos in contract negotiation



#### **Products**

- New user experience will be delivered in H2 2025
- Developing Al-powered products; launched Ovie a Gen Al-powered Care Assistant
- Achieved ISO 42001 certification for its Al Management System



#### **Productivity**

- Restructured operations to align with strategic priorities
- Continued focus on operating more efficiently
- Early efficiency gains from the adoption of Alpowered tools across the business
- Progressing towards more efficient deployments



### Thank You





# Oneview / the connected care experience company

A&P